14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
ESPR vs BGM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ESPR carries a Unified Composite Score of 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin), whereas BGM carries 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin).
Growth vs. Quality Trade-Off: ESPR earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. BGM 59.6/100 HOLD) and 1.86β · 6% Vol risk profile, whereas BGM leads top-line expansion (+69.8% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ESPR vs BGM. Trailing 12-month operating profitability (ESPR -8.2% vs BGM -23.4%) and valuation multiples (ESPR 10.9x vs BGM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment40.3% of Rev ($19M)
90D Engineering Disclosures0 Published
Investor FAQ ESPR vs BGM Key Questions & Quantitative Answers
As of Nov 19, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ESPR carries a Unified Composite Score of 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin), whereas BGM carries 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin). Growth vs. Quality Trade-Off: ESPR earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. BGM 59.6/100 HOLD) and 1.86β · 6% Vol risk profile, whereas BGM leads top-line expansion (+69.8% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
ESPR leads the Growth & Scale pillar: ESPR posts +23.2% YoY revenue growth and +0.0% YoY earnings growth on $418M TTM revenue (57.8% gross margin, -8.2% operating margin), compared with BGM at +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin). On trailing 12-month operating scale, ESPR generates $418M in USD-normalized revenue versus $48M for BGM. In operating R&D and SG&A reinvestment, ESPR deploys 66.0% of Rev ($276M) (0 90-day corporate R&D disclosures) versus 40.3% of Rev ($19M) (0 disclosures) for BGM.
ESPR screens cheaper on headline valuation multiples. ESPR trades at 10.9x Forward P/E, 4.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (-4.4% FCF margin), whereas BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ESPR (-260.8% ROE) versus BGM (-7.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ESPR carries 12.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.86β · 6% Vol realized risk). By comparison, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.